INFANT'S ADVIL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for INFANT'S ADVIL (INFANT'S ADVIL).

How it works

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.

What the body does with it

Metabolism	Primarily hepatic via CYP2C9 and CYP2C8; also undergoes glucuronidation.
Excretion	Renal excretion of metabolites (primarily glucuronide and sulfate conjugates of ibuprofen) accounts for approximately 90% of elimination, with less than 10% excreted unchanged in urine. Biliary/fecal excretion is minimal (<5%).
Half-life	Terminal elimination half-life is approximately 1.5 to 2 hours in infants and children, which is shorter than in adults (2-4 hours). This shorter half-life reflects higher clearance in pediatric populations and has clinical implications for dosing frequency (typically every 6-8 hours).
Protein binding	Approximately 99% bound to plasma proteins, primarily albumin. This high binding can affect distribution and elimination, especially in conditions with hypoalbuminemia.
Volume of Distribution	Approximately 0.1-0.2 L/kg in infants and children, indicating limited extravascular distribution. This low Vd correlates with high plasma protein binding and minimal tissue penetration.
Bioavailability	Oral suspension: >80% bioavailability (first-pass metabolism is minimal but variable). The infant formulation has similar bioavailability to adult tablets, though absorption may be slightly more rapid due to liquid form.
Onset of Action	Oral administration (suspension): Antipyretic effect begins within 15-30 minutes, with peak effect at 1-2 hours. Analgesic effect onset is similar.
Duration of Action	Antipyretic and analgesic effects last approximately 6-8 hours. Duration may be slightly shorter in infants due to faster clearance. Clinical note: The suspension formulation is designed for 6-8 hour dosing intervals.

Classification & Brands

Dosing & administration

200-400 mg orally every 4-6 hours as needed; maximum daily dose 1200 mg.

Dosage form	SUSPENSION/DROPS
Renal impairment	eGFR 30-60 mL/min: reduce dose by 25-50%; eGFR <30 mL/min: avoid use.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Pediatric use	5-10 mg/kg/dose orally every 6-8 hours as needed; maximum single dose 400 mg; maximum daily dose 40 mg/kg or 1200 mg (whichever is less).
Geriatric use	Start at lowest effective dose (e.g., 200 mg) and limit daily dose to 800 mg due to increased risk of GI bleeding and renal impairment.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for INFANT'S ADVIL (INFANT'S ADVIL).

Breastfeeding	Ibuprofen is excreted into breast milk in very low amounts (M/P ratio approximately 0.6). Considered compatible with breastfeeding based on low infant dose. Caution in high maternal doses or prolonged use.
Teratogenic Risk	First trimester: NSAIDs may increase risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Second trimester: Generally considered lower risk but use is not recommended unless clearly needed. Third trimester: Avoid due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.

Warnings & precautions

■ FDA Black Box Warning

NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.

Side Effect Profile

Serious Effects

Absolute Contraindications

Known hypersensitivity to ibuprofen or any component; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of CABG surgery; patients with active gastrointestinal bleeding; severe heart failure; severe renal impairment.

Clinical Precautions

Precautions

Cardiovascular thrombotic events, gastrointestinal bleeding, ulceration, and perforation; renal toxicity; hypertension; anaphylactoid reactions; serious skin reactions; hematologic toxicity; use with caution in patients with asthma; avoid use in late pregnancy.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

INFANT'S ADVIL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for INFANT'S ADVIL (INFANT'S ADVIL).

How it works

What the body does with it

Metabolism	Primarily hepatic via CYP2C9 and CYP2C8; also undergoes glucuronidation.
Excretion	Renal excretion of metabolites (primarily glucuronide and sulfate conjugates of ibuprofen) accounts for approximately 90% of elimination, with less than 10% excreted unchanged in urine. Biliary/fecal excretion is minimal (<5%).
Half-life	Terminal elimination half-life is approximately 1.5 to 2 hours in infants and children, which is shorter than in adults (2-4 hours). This shorter half-life reflects higher clearance in pediatric populations and has clinical implications for dosing frequency (typically every 6-8 hours).
Protein binding	Approximately 99% bound to plasma proteins, primarily albumin. This high binding can affect distribution and elimination, especially in conditions with hypoalbuminemia.
Volume of Distribution	Approximately 0.1-0.2 L/kg in infants and children, indicating limited extravascular distribution. This low Vd correlates with high plasma protein binding and minimal tissue penetration.
Bioavailability	Oral suspension: >80% bioavailability (first-pass metabolism is minimal but variable). The infant formulation has similar bioavailability to adult tablets, though absorption may be slightly more rapid due to liquid form.
Onset of Action	Oral administration (suspension): Antipyretic effect begins within 15-30 minutes, with peak effect at 1-2 hours. Analgesic effect onset is similar.
Duration of Action	Antipyretic and analgesic effects last approximately 6-8 hours. Duration may be slightly shorter in infants due to faster clearance. Clinical note: The suspension formulation is designed for 6-8 hour dosing intervals.

Classification & Brands

Dosing & administration

200-400 mg orally every 4-6 hours as needed; maximum daily dose 1200 mg.

Dosage form	SUSPENSION/DROPS
Renal impairment	eGFR 30-60 mL/min: reduce dose by 25-50%; eGFR <30 mL/min: avoid use.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Pediatric use	5-10 mg/kg/dose orally every 6-8 hours as needed; maximum single dose 400 mg; maximum daily dose 40 mg/kg or 1200 mg (whichever is less).
Geriatric use	Start at lowest effective dose (e.g., 200 mg) and limit daily dose to 800 mg due to increased risk of GI bleeding and renal impairment.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for INFANT'S ADVIL (INFANT'S ADVIL).

Breastfeeding	Ibuprofen is excreted into breast milk in very low amounts (M/P ratio approximately 0.6). Considered compatible with breastfeeding based on low infant dose. Caution in high maternal doses or prolonged use.
Teratogenic Risk	First trimester: NSAIDs may increase risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Second trimester: Generally considered lower risk but use is not recommended unless clearly needed. Third trimester: Avoid due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.